AB0936 IMPACT OF DIFFERENT BDMARDS ON PATIENT REPORTED OUTCOMES IN AXIAL SPONDYLOARTHRITIS: A SYSTEMATIC REVIEW OF THE LITERATURE AND META-ANALYSIS

Background Pain, fatigue and altered quality of life are frequent complaints in axial spondyloarthritis (axSpA), with an impact on disease activity evaluation, regardless radiographic or non-radiographic phenotype. No study compares face to the effects biologic DMARDs (bDMARDs) patient reported outcomes (PROs). Objectives To evaluate (bDMARDs: anti-TNF anti-IL17) three PROs (pain, fatigue, life) patients (axSpA). Methods A systematic review was performed PubMed, Embase until May 2022, abstracts from EULAR ACR meetings for past 3 years. The search included all randomized controlled trials bDMARDS reporting data pain (“total back pain”, “nocturnal pain”), (FACIT-F) (ASQoL SF36 PCS MCS) axSpA. Statistical analysis used inverse variance method obtain results as mean differences, which were visualized by forest plot. Variation between studies assessed calculating heterogeneity (I²) Cochran’s Q test. Results total 25 final analysis, a number 8457 patients. Compared placebo, treatment bDMARDs associated significant improvement pain, life. differences -1.47 (95% CI (-1.72, -1.22)) -1.67 (-2.06, -1.28)) nocturnal 4.47 (3.23, 5. 72)) FACIT-F, -2.59 (-2.68, -2.49)) ASQoL, 3.68 (3.21, 4.15)) 2.79 (1.83, 3.75)) MCS. For subgroup comparing different bDMARDs, numerically superior anti-TNF, but difference not because confidence intervals overlapping. There no other anti-IL17. Heterogeneity weak except pain” scale. axSpA phenotypes, different, mental component score less improved Conclusion (anti-TNF significantly improve compared placebo observed anti-IL-17, nor axSpA, SF36. References: Nil Acknowledgements Thomas Barnetche statistical analysis. Disclosure Interests Emma Gadon: None declared, Thibaud Loupret: Camille Lemaçon: Philippe Bertin Speakers bureau: Pfizer, Abbvie, UCB, Lilly, Novartis, Pascale Vergne-Salle Novartis.